Drug- or toxin-induced pulmonary arterial hypertension is a Group 1 pulmonary arterial hypertension subtype in which exposure to a culprit drug or toxin is judged causal or contributory. Established exposures include historical anorexigens, methamphetamine, dasatinib, and toxic rapeseed oil, while other agents remain lower-certainty signals. The clinical syndrome shares the hemodynamic, pulmonary vascular remodeling, and right-heart consequences of pulmonary arterial hypertension, with exposure history central to diagnosis and management.
Ask a research question about Drug- or Toxin-Induced Pulmonary Arterial Hypertension. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Drug- or Toxin-Induced Pulmonary Arterial Hypertension
creation_date: "2026-05-05T01:33:38Z"
updated_date: "2026-05-05T03:48:15Z"
description: >-
Drug- or toxin-induced pulmonary arterial hypertension is a Group 1 pulmonary
arterial hypertension subtype in which exposure to a culprit drug or toxin is
judged causal or contributory. Established exposures include historical
anorexigens, methamphetamine, dasatinib, and toxic rapeseed oil, while other
agents remain lower-certainty signals. The clinical syndrome shares the
hemodynamic, pulmonary vascular remodeling, and right-heart consequences of
pulmonary arterial hypertension, with exposure history central to diagnosis
and management.
category: Environmental
disease_term:
preferred_term: drug- or toxin-induced pulmonary arterial hypertension
term:
id: MONDO:0017149
label: drug- or toxin-induced pulmonary arterial hypertension
parents:
- Vascular disorder
synonyms:
- Drug-induced PAH
- Toxin-induced PAH
- Drug- or toxin-associated pulmonary arterial hypertension
- DTI-PAH
pathophysiology:
- name: Drug/toxin-triggered pulmonary endothelial dysfunction
description: >-
Culprit drugs or toxins can injure or dysregulate pulmonary arterial
endothelium, creating a permissive vascular state for downstream smooth
muscle growth and remodeling.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
locations:
- preferred_term: pulmonary artery
term:
id: UBERON:0002012
label: pulmonary artery
biological_processes:
- preferred_term: endothelial cell dysfunction
modifier: ABNORMAL
evidence:
- reference: DOI:10.21542/gcsp.2019.19
reference_title: "Drug- and toxin-induced pulmonary arterial hypertension: Current state of the literature"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Drug- and toxin-induced pulmonary arterial hypertension (PAH) is an increasingly important sub-group of group 1 pulmonary hypertension (PH).
explanation: This review establishes the disease as a Group 1 pulmonary hypertension subtype.
- reference: PMID:23972547
reference_title: Drugs induced pulmonary arterial hypertension.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Recently several studies raised the potential endothelial dysfunction that could be induced by interferon, and few cases of PAH have been reported with interferon therapy.
explanation: This supports drug-associated endothelial dysfunction as one mechanistic component of drug-induced PAH.
downstream:
- target: Pulmonary artery smooth muscle proliferation
description: Endothelial dysfunction promotes a pro-remodeling pulmonary arterial environment.
- name: Pulmonary artery smooth muscle proliferation
description: >-
Exposure-associated signaling can increase pulmonary arterial smooth muscle
cell growth, narrowing the pulmonary vascular bed and feeding progressive
vascular remodeling.
cell_types:
- preferred_term: vascular smooth muscle cell
term:
id: CL:0000359
label: vascular associated smooth muscle cell
locations:
- preferred_term: pulmonary artery
term:
id: UBERON:0002012
label: pulmonary artery
biological_processes:
- preferred_term: positive regulation of smooth muscle cell proliferation
modifier: INCREASED
term:
id: GO:0048661
label: positive regulation of smooth muscle cell proliferation
evidence:
- reference: PMID:23972547
reference_title: Drugs induced pulmonary arterial hypertension.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The supposed mechanism is an increase in serotonin levels, which was demonstrated to act as a growth factor for the pulmonary arterial smooth muscle cells.
explanation: This directly supports pulmonary arterial smooth muscle growth signaling in drug-associated PAH.
downstream:
- target: Pulmonary vascular remodeling and increased resistance
description: Smooth muscle proliferation contributes to occlusive pulmonary vascular remodeling.
- name: Pulmonary vascular remodeling and increased resistance
description: >-
Progressive pulmonary microvascular obliteration and remodeling increase
pulmonary vascular resistance, elevating right ventricular afterload and
driving PAH morbidity.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
- preferred_term: vascular smooth muscle cell
term:
id: CL:0000359
label: vascular associated smooth muscle cell
locations:
- preferred_term: pulmonary artery
term:
id: UBERON:0002012
label: pulmonary artery
evidence:
- reference: PMID:23972547
reference_title: Drugs induced pulmonary arterial hypertension.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Pulmonary arterial hypertension (PAH) is a rare disorder characterized by progressive obliteration of the pulmonary microvasculature, resulting in elevated pulmonary vascular resistance and premature death.
explanation: This directly supports the pulmonary vascular remodeling and elevated resistance mechanism.
- name: Serotonergic anorexigen smooth muscle growth signaling
description: >-
Appetite suppressant drugs such as aminorex, fenfluramine derivatives, and
benfluorex are linked to PAH; serotonin-mediated pulmonary arterial smooth
muscle growth is a proposed mechanism.
cell_types:
- preferred_term: vascular smooth muscle cell
term:
id: CL:0000359
label: vascular associated smooth muscle cell
biological_processes:
- preferred_term: positive regulation of smooth muscle cell proliferation
modifier: INCREASED
term:
id: GO:0048661
label: positive regulation of smooth muscle cell proliferation
evidence:
- reference: PMID:23972547
reference_title: Drugs induced pulmonary arterial hypertension.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
appetite suppressant drugs, such as aminorex, fenfluramine derivatives and benfluorex. These drugs have been confirmed to be risk factors for PAH and were withdrawn from the market.
explanation: This supports the definite anorexigen exposure class.
- reference: PMID:23972547
reference_title: Drugs induced pulmonary arterial hypertension.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The supposed mechanism is an increase in serotonin levels, which was demonstrated to act as a growth factor for the pulmonary arterial smooth muscle cells.
explanation: This supports serotonergic smooth muscle growth as a mechanistic hypothesis for appetite-suppressant-associated PAH.
downstream:
- target: Pulmonary artery smooth muscle proliferation
description: Serotonergic anorexigen signaling directly feeds pulmonary arterial smooth muscle growth.
phenotypes:
- category: Cardiovascular
name: Pulmonary arterial hypertension
diagnostic: true
description: Pre-capillary PAH is the defining hemodynamic phenotype.
phenotype_term:
preferred_term: Pulmonary arterial hypertension
term:
id: HP:0002092
label: Pulmonary arterial hypertension
evidence:
- reference: DOI:10.3390/biomedicines13071773
reference_title: "State of the Art in Pulmonary Arterial Hypertension: Molecular Basis, Imaging Modalities, and Right Heart Failure Treatment"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Pulmonary arterial hypertension (PAH) is a specific subset of PH characterized by a normal pulmonary arterial wedge pressure (PAWP), combined with elevated mPAP and increased pulmonary vascular resistance (PVR)
explanation: This supports the defining PAH hemodynamic phenotype.
- category: Respiratory
name: Dyspnea
description: Exertional dyspnea is a common presenting symptom of pulmonary arterial hypertension.
phenotype_term:
preferred_term: Dyspnea
term:
id: HP:0002094
label: Dyspnea
- category: Cardiovascular
name: Right ventricular failure
description: Elevated pulmonary vascular resistance increases right ventricular afterload and can progress to right-sided heart failure.
phenotype_term:
preferred_term: Right ventricular failure
term:
id: HP:0001708
label: Right ventricular failure
evidence:
- reference: DOI:10.3390/biomedicines13071773
reference_title: "State of the Art in Pulmonary Arterial Hypertension: Molecular Basis, Imaging Modalities, and Right Heart Failure Treatment"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Dysregulation of these pathways leads to a progressive vasculopathy marked by vasoconstriction, vascular proliferation, elevated right heart afterload, and ultimately right-sided heart failure.
explanation: This directly supports right-heart failure as a downstream PAH consequence.
- category: Cardiovascular
name: Syncope
description: Syncope can occur in advanced PAH when cardiac output cannot meet demand during exertion or hemodynamic stress.
phenotype_term:
preferred_term: Syncope
term:
id: HP:0001279
label: Syncope
- category: Constitutional
name: Fatigue
description: Fatigue reflects reduced exercise capacity and cardiopulmonary reserve in pulmonary arterial hypertension.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
evidence:
- reference: DOI:10.1183/13993003.01325-2024
reference_title: Treatment algorithm for pulmonary arterial hypertension
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Pulmonary arterial hypertension leads to significant impairment in haemodynamics, right heart function, exercise capacity, quality of life and survival.
explanation: This supports impaired exercise capacity and quality of life as PAH impacts; fatigue is retained as the review-supported symptom-level expression.
- category: Cardiovascular
name: Peripheral edema
description: Peripheral edema can occur with right-heart congestion in advanced pulmonary arterial hypertension.
phenotype_term:
preferred_term: Peripheral edema
term:
id: HP:0012398
label: Peripheral edema
environmental:
- name: Definite drug or toxin exposure
description: >-
Definite exposure classes include methamphetamine, historical appetite
suppressants such as aminorex and fenfluramine derivatives, benfluorex,
dasatinib, and toxic rapeseed oil.
presence: Positive
chemicals:
- methamphetamine
- aminorex
- fenfluramine
- dasatinib
evidence:
- reference: DOI:10.21542/gcsp.2019.19
reference_title: "Drug- and toxin-induced pulmonary arterial hypertension: Current state of the literature"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Currently, drugs and toxins are classified into “possible” and “definite” risk factors for PAH.
explanation: This supports graded exposure classification.
- reference: DOI:10.1111/bcp.15436
reference_title: "Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Since the 1960s, several drugs have been linked to the onset or aggravation of pulmonary arterial hypertension (PAH): dasatinib, some amphetamine‐like appetite suppressants (aminorex, fenfluramine, dexfenfluramine, benfluorex) and recreational drugs (methamphetamine).
explanation: This pharmacovigilance analysis lists established drug classes and methamphetamine.
- name: Methamphetamine exposure
description: >-
Methamphetamine-associated PAH is an increasingly recognized stimulant-linked
form with rising U.S. hospitalization burden.
presence: Positive
chemicals:
- methamphetamine
evidence:
- reference: DOI:10.3389/fcvm.2024.1445193
reference_title: "Trends and patterns in pulmonary arterial hypertension-associated hospital admissions among methamphetamine users: a decade-long study"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A significant increase was evident in patients with pulmonary arterial hypertension (PAH) and concurrent methamphetamine use (9.2-fold).
explanation: This supports the rising burden of methamphetamine-associated PAH hospitalizations.
- reference: DOI:10.3389/fcvm.2024.1445193
reference_title: "Trends and patterns in pulmonary arterial hypertension-associated hospital admissions among methamphetamine users: a decade-long study"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
An overall adjusted prevalence ratio (PR) for PAH hospitalizations among concurrent methamphetamine users was 32.19 (CI = 31.19–33.22) compared to non-users.
explanation: This quantifies the hospitalization association with methamphetamine use.
genetic:
- name: BMPR2 susceptibility
association: Predisposing
presence: Positive
gene_term:
preferred_term: BMPR2
notes: >-
Falcon review synthesis describes BMPR2 as a susceptibility factor in a
gene-environment two-hit model for some drug- or toxin-associated PAH. The
cached review abstract supports genetic underpinnings generally but does
not isolate BMPR2, so no ontology binding or stronger evidence claim is
asserted here.
evidence:
- reference: DOI:10.21542/gcsp.2019.19
reference_title: "Drug- and toxin-induced pulmonary arterial hypertension: Current state of the literature"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
novel clinical and basic science studies are beginning to unravel the biologic factors and genetic underpinnings responsible for disease development.
explanation: This supports genetic susceptibility as a general DTI-PAH theme, while BMPR2 specificity is retained in notes from the deep-research synthesis.
diagnosis:
- name: Right heart catheterization and exclusion of alternate PH causes
description: >-
Diagnosis requires confirming pre-capillary PAH physiology, assessing
exposure history, and excluding other causes of pulmonary hypertension.
evidence:
- reference: DOI:10.3390/biomedicines13071773
reference_title: "State of the Art in Pulmonary Arterial Hypertension: Molecular Basis, Imaging Modalities, and Right Heart Failure Treatment"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The gold standard for diagnosis remains invasive right heart catheterization.
explanation: This supports invasive hemodynamic confirmation.
- reference: DOI:10.21542/gcsp.2019.19
reference_title: "Drug- and toxin-induced pulmonary arterial hypertension: Current state of the literature"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
it is often difficult to identify patients early and demonstrate causality between drugs and PAH.
explanation: This supports careful exposure attribution and differential diagnosis.
- name: Vasoreactivity assessment at index catheterization
description: >-
Acute vasoreactivity testing can be considered during diagnostic right-heart
catheterization to guide calcium-channel-blocker candidacy and risk
stratification, although applicability depends on the clinical context.
notes: >-
Added from the Falcon review suggestion; the cached abstracts support
catheter-based PAH diagnosis but do not provide a direct vasoreactivity
testing quote.
treatments:
- name: Culprit drug or toxin withdrawal
description: >-
Removal of the implicated exposure is central when feasible; reversibility
varies by agent and disease severity.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
target_mechanisms:
- target: Drug/toxin-triggered pulmonary endothelial dysfunction
treatment_effect: INHIBITS
description: Removing the culprit exposure reduces ongoing exposure-driven vascular injury when reversible.
evidence:
- reference: PMID:23972547
reference_title: Drugs induced pulmonary arterial hypertension.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Dasatinib, a dual Src/Abl kinase inhibitor, used in the treatment of chronic myelogenous leukaemia was associated with cases of severe PAH, in part reversible after its withdrawal.
explanation: This directly supports reversibility after withdrawal for a recognized culprit drug.
- name: Risk-stratified PAH pathway therapy
description: >-
Persistent or higher-risk disease is treated using standard PAH
pathway-based therapies, often in combination and escalated by risk.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: endothelin receptor antagonist
- preferred_term: phosphodiesterase-5 inhibitor
- preferred_term: prostacyclin pathway therapy
- preferred_term: BMP/activin signaling therapy
target_mechanisms:
- target: Pulmonary vascular remodeling and increased resistance
treatment_effect: MODULATES
description: PAH pathway therapies modulate vasoconstriction and proliferative signaling that drive elevated pulmonary vascular resistance.
evidence:
- reference: DOI:10.1183/13993003.01325-2024
reference_title: Treatment algorithm for pulmonary arterial hypertension
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Current therapies have mechanisms of action involving signallingviaone of four pathways: endothelin-1, nitric oxide, prostacyclin and bone morphogenetic protein/activin signalling.
explanation: This supports pathway-targeted PAH therapy.
- reference: DOI:10.1183/13993003.01325-2024
reference_title: Treatment algorithm for pulmonary arterial hypertension
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Efficacy has generally been greater with therapeutic combinations and with parenteral therapy compared with monotherapy or nonparenteral therapies, and maximal medical therapy is now four-drug therapy.
explanation: This supports combination and escalation strategies in PAH management.
progression:
- phase: Methamphetamine-associated prognosis
notes: >-
The Falcon review surfaced lower reported survival in methamphetamine-
associated PAH than idiopathic PAH; exact 5- and 10-year survival figures
were not added because the currently cached abstracts do not provide a
directly quotable sentence for those values.
evidence:
- reference: DOI:10.1183/13993003.01325-2024
reference_title: Treatment algorithm for pulmonary arterial hypertension
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Pulmonary arterial hypertension leads to significant impairment in haemodynamics, right heart function, exercise capacity, quality of life and survival.
explanation: This supports survival as a clinically important PAH outcome, while methamphetamine-specific survival values are retained only in notes.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on Drug- or Toxin-Induced Pulmonary Arterial Hypertension covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
Drug- or toxin-induced pulmonary arterial hypertension (DTI-PAH) is a Group 1 pulmonary arterial hypertension (PAH) subtype in the World Symposium/ESC-ERS clinical classification, in which exposure to specific drugs or toxins is judged causally implicated (with strength graded as “definite” or “possible”). Diagnosis generally requires confirmation of pre-capillary PH by right heart catheterization and exclusion of other causes of pulmonary hypertension, plus a compatible exposure history; management includes cessation of the culprit exposure, risk-stratified PAH therapy, and in some etiologies (e.g., interferon- or dasatinib-associated PAH) a short period of observation may be reasonable for low-risk patients to assess reversibility. Recent 2023–2024 literature emphasizes: (i) rising burden of methamphetamine-associated PAH, including large increases in U.S. hospitalizations and high adjusted prevalence ratios among methamphetamine users; (ii) continued refinement of evidence-based culprit lists; and (iii) newer disease-modifying treatments in PAH generally (e.g., sotatercept) now incorporated into updated algorithms. (dardi2024riskstratificationand pages 22-24, dardi2024riskstratificationand pages 66-68, chin2024treatmentalgorithmfor pages 11-12, iwata2024trendsandpatterns pages 1-2, chin2024treatmentalgorithmfor pages 7-8, chin2024treatmentalgorithmfor pages 2-3)
DTI-PAH (also termed drug- or toxin-associated PAH) is a subtype of Group 1 PAH in which PAH occurs in individuals exposed to a suspected causal drug/toxin. Contemporary guidelines/reviews emphasize that drug/toxin-associated PAH can be clinically indistinguishable from idiopathic PAH and often requires careful exclusion of other etiologies before attribution. (dardi2024riskstratificationand pages 66-68, iii2020drugandtoxininduced pages 1-3)
Hemodynamic definition of PAH (pre-capillary PH) by right heart catheterization includes mPAP >20 mmHg, PAWP <15 mmHg, and increased PVR (e.g., PVR >2 WU noted in recent definitions). (shafeghat2025stateofthe pages 2-4, chin2024treatmentalgorithmfor pages 5-7)
Common terms used in recent authoritative sources include: - “drug- or toxin-associated PAH” and abbreviation DPAH (ERJ 2024). (dardi2024riskstratificationand pages 66-68, dardi2024riskstratificationand pages 21-22) - “drug-/toxin-induced PAH” and abbreviation DT-PAH (ERJ 2024). (chin2024treatmentalgorithmfor pages 1-2, chin2024treatmentalgorithmfor pages 5-7)
Most “disease information” in this report is derived from aggregated disease-level resources (7th WSPH/ESC-ERS aligned ERJ documents, narrative and systematic reviews) plus large administrative-database epidemiology for methamphetamine-associated PAH. (chin2024treatmentalgorithmfor pages 5-7, dardi2024riskstratificationand pages 22-24, iwata2024trendsandpatterns pages 1-2)
Guidelines classify implicated exposures as definite or possible associations with PAH; “definite” is supported by outbreaks, epidemiologic case-control studies, or large multicentre series, while “possible” is supported by multiple case series or mechanistic similarity. (dardi2024riskstratificationand pages 22-24, iii2020drugandtoxininduced pages 1-3)
Definite: aminorex, benfluorex, dasatinib, dexfenfluramine, fenfluramine, methamphetamines, toxic rapeseed oil. (dardi2024riskstratificationand pages 22-24)
Possible: examples include alkylating agents (cyclophosphamide, mitomycin C), amphetamines, bosutinib, cocaine, diazoxide, sofosbuvir, Qing-Dai/indirubin, interferon α/β, leflunomide, L-tryptophan, phenylpropanolamine, ponatinib, carfilzomib, trichloroethylene, St John’s Wort. (dardi2024riskstratificationand pages 22-24)
Exposure-related risk - Methamphetamine is explicitly classified as a definite associated exposure and is increasingly recognized in U.S. centers. (dardi2024riskstratificationand pages 22-24, dardi2024riskstratificationand pages 66-68)
Host susceptibility (genetic and biologic factors) - Evidence supports a gene–environment (“two-hit”) model, in which only a subset of exposed individuals develop overt PAH. (iii2020drugandtoxininduced pages 19-21) - In fenfluramine-associated PAH, BMPR2 mutations were reported at frequencies similar to sporadic PAH and BMPR2 carriers required shorter exposure durations before developing PAH—supporting genetic susceptibility modifying drug-triggered disease. (seferian2013drugsinducedpulmonary pages 2-3)
Suggested ontology terms - CHEBI examples (non-exhaustive): methamphetamine (CHEBI term exists), dasatinib (CHEBI term exists), fenfluramine (CHEBI term exists).
Symptoms of PAH are often nonspecific early and reflect progressive RV dysfunction: - Progressive exertional dyspnoea is the cardinal symptom. (dardi2024riskstratificationand pages 24-25) - Other reported symptoms/signs in PAH include fatigue, palpitations, chest pain, syncope, fluid retention/abdominal distension/weight gain in advanced disease. (coman2025updatesonthe pages 1-2)
Right heart catheterization defines pre-capillary disease using mPAP, PAWP, and PVR thresholds (e.g., mPAP >20 mmHg, PAWP <15 mmHg, and elevated PVR). (shafeghat2025stateofthe pages 2-4, chin2024treatmentalgorithmfor pages 5-7)
(Phenotype concepts supported by PAH symptom descriptions and RV remodeling consequences in the retrieved texts; formal HPO mapping is suggested rather than asserted as directly coded in the sources.) (coman2025updatesonthe pages 1-2, shafeghat2025stateofthe pages 2-4)
DTI-PAH is primarily environmental, but genetic susceptibility is important: - BMPR2 is highlighted as a major PAH susceptibility gene in PAH broadly and in gene–environment contexts. (seferian2013drugsinducedpulmonary pages 2-3, shafeghat2025stateofthe pages 2-4) - Additional PAH genes in the BMP/TGF-β axis reported in PAH pathophysiology reviews include ENG, ACVRL1, CAV1, SMAD9, GDF2. (correale2025pathophysiologyofpulmonary pages 2-4)
See the summary table artifact below for definite vs possible drug/toxin exposures. (dardi2024riskstratificationand pages 22-24)
DTI-PAH is mechanistically heterogeneous; several convergent pathways are repeatedly implicated.
Fenfluramine-class drugs are potent 5-HT uptake inhibitors; increased serotonin can act as a growth factor for pulmonary artery smooth muscle cells, promoting vascular remodeling. (seferian2013drugsinducedpulmonary pages 2-3)
Drug/toxin exposure plus host predisposition is a recurring mechanistic frame; only a subset of exposed individuals develop PAH. (iii2020drugandtoxininduced pages 19-21)
PAH pathology is described as endothelial-centered, with plexiform lesions and distal arteriolar remodeling. (shafeghat2025stateofthe pages 2-4)
ROCK pathway activity is increased in PAH and serotonin-related vasoconstriction/proliferation can converge on ROCK signaling; ROCK inhibition can acutely reduce pulmonary hemodynamic load in studies, motivating therapeutic exploration. (shah2023newdrugsand pages 11-13)
Guidelines caution that DTI-PAH can present with features of PVOD/PCH, especially after alkylating agents (e.g., mitomycin C, cyclophosphamide), affecting diagnosis and therapy safety. (dardi2024riskstratificationand pages 66-68)
Suggested GO biological process terms (examples) - Pulmonary artery smooth muscle cell proliferation - Endothelial cell apoptosis - Vascular remodeling - Hypoxic pulmonary vasoconstriction
Suggested CL cell types (examples) - Pulmonary artery endothelial cell - Pulmonary artery smooth muscle cell - Macrophage
(These ontology suggestions reflect mechanisms discussed in the retrieved reviews rather than explicit ontology annotations in the cited papers.) (shafeghat2025stateofthe pages 2-4, shah2023newdrugsand pages 11-13)
Suggested UBERON terms (examples) - Pulmonary artery - Pulmonary arteriole - Right ventricle
Guideline-level estimates for PAH overall (not limited to DTI-PAH) include: - PAH incidence ≈ 6 per million adults and prevalence ≈ 48–55 per million in developed-country registries. (dardi2024riskstratificationand pages 22-24)
A U.S. National Inpatient Sample analysis (2008–2020) reported: - 9.2-fold increase in PAH hospitalizations with concurrent methamphetamine use. (iwata2024trendsandpatterns pages 1-2) - Adjusted prevalence ratio for PAH hospitalization among methamphetamine users vs non-users: PR 32.19 (95% CI 31.19–33.22). (iwata2024trendsandpatterns pages 1-2, iwata2024trendsandpatterns pages 6-7) - Methamphetamine-associated PAH hospitalizations: 59.16% male; age distribution concentrated in 41–64 years (45.77%) and 26–40 years (37.52%). (iwata2024trendsandpatterns pages 3-4)
Direct abstract quotes (Frontiers in Cardiovascular Medicine, 2024-10): - “A significant increase was evident in patients with pulmonary arterial hypertension (PAH) and concurrent methamphetamine use (9.2-fold).” (iwata2024trendsandpatterns pages 1-2) - “An overall adjusted prevalence ratio (PR) for PAH hospitalizations among concurrent methamphetamine users was 32.19 (CI = 31.19–33.22) compared to non-users.” (iwata2024trendsandpatterns pages 1-2)
Guideline workup includes ECG, chest radiograph, PFTs/DLCO and ABG, labs (including BNP/NT-proBNP), and multimodality imaging; evaluation aims to exclude other PH groups and comorbidities. (dardi2024riskstratificationand pages 24-25, dardi2024riskstratificationand pages 31-32)
The 7th WSPH/ERJ 2024 algorithm emphasizes initial risk assessment and combination therapy escalation. (chin2024treatmentalgorithmfor pages 2-3, chin2024treatmentalgorithmfor media 169fd8c9) - Non–high-risk: initial combination ERA + PDE-5i. (chin2024treatmentalgorithmfor pages 5-7) - High-risk: parenteral prostacyclin pathway agent + ERA + PDE-5i (initial triple therapy) and early transplant evaluation. (chin2024treatmentalgorithmfor pages 5-7, chin2024treatmentalgorithmfor pages 7-8) - Escalation can yield maximal four-drug therapy, adding an activin-signalling inhibitor (e.g., sotatercept) to ERA + PDE-5i/sGCS + parenteral prostacyclin. (chin2024treatmentalgorithmfor pages 2-3)
Recent development (2024): add-on sotatercept improved outcomes in advanced PAH trials and is incorporated into escalation options in the ERJ 2024 treatment algorithm. (chin2024treatmentalgorithmfor pages 7-8, chin2024treatmentalgorithmfor pages 2-3)
Primary prevention is largely exposure prevention and pharmacovigilance: - Public-health and clinical emphasis on avoiding/ceasing implicated drugs/toxins (especially illicit stimulants) and maintaining high suspicion for DTI-PAH in unexplained exertional dyspnea. (dardi2024riskstratificationand pages 66-68, iii2020drugandtoxininduced pages 19-21)
DTI-PAH and PAH mechanisms are studied using several rodent and in vitro systems: - Monocrotaline (MCT) rodent models (rats) and hypoxia models are commonly used experimental PH/PAH models. (shah2023newdrugsand pages 16-17, shah2023newdrugsand pages 11-13) - SU5416 + hypoxia (Sugen/hypoxia) rat models are used to study severe pulmonary vascular remodeling and RV failure; SU5416 causes pulmonary endothelial apoptosis and is used in combination insult models. (shah2023newdrugsand pages 18-19, yeh2025molecularpathogenesisof pages 18-19) - In vitro serotonin-pathway relevant models include: anorexigens inhibiting potassium currents in pulmonary vascular smooth muscle preparations and MDMA producing 5HT2B-mediated mitogenic effects in human cell systems (mechanistic analogy to anorexigens). (iii2020drugandtoxininduced pages 19-21)
Limitations: pharmacovigilance analyses emphasize that extrapolating animal results to human drug-induced PAH is challenging. (hlavaty2022identifyingnewdrugs pages 7-8)
| Agent/exposure | Evidence category | Typical context/use | Key mechanistic hypotheses | Notes on reversibility/management | Key citations and year |
|---|---|---|---|---|---|
| Aminorex | Definite | Historical anorexigen/appetite suppressant | Serotonergic pathway; appetite suppressants can inhibit K+ currents and promote pulmonary vasoconstriction/remodeling | Withdraw exposure; historical outbreak established causality; manage as PAH if persistent (dardi2024riskstratificationand pages 22-24, iii2020drugandtoxininduced pages 1-3, seferian2013drugsinducedpulmonary pages 2-3) | Seferian 2013, DOI:10.1016/j.lpm.2013.07.005; Ramirez 2020, DOI:10.21542/gcsp.2019.19; Dardi 2024, DOI:10.1183/13993003.01323-2024 |
| Fenfluramine / Dexfenfluramine | Definite | Anorexigen/appetite suppressants | 5-HT uptake inhibition; 5-HT/5-HT2B-driven PASMC proliferation; gene–environment interaction with BMPR2 susceptibility | Withdraw exposure; clinically resembles idiopathic/heritable PAH; persistent disease may require standard PAH therapy (seferian2013drugsinducedpulmonary pages 1-2, dardi2024riskstratificationand pages 22-24, seferian2013drugsinducedpulmonary pages 2-3) | Seferian 2013, DOI:10.1016/j.lpm.2013.07.005; Dardi 2024, DOI:10.1183/13993003.01323-2024 |
| Benfluorex | Definite | Antidiabetic/anorexigen exposure, especially historical French use | Norfenfluramine-related serotonergic toxicity; pulmonary vascular and valvular toxicity | Stop agent; monitor for PAH and valvular disease; treat residual PAH per guidelines (seferian2013drugsinducedpulmonary pages 1-2, dardi2024riskstratificationand pages 22-24, iii2020drugandtoxininduced pages 1-3) | Seferian 2013, DOI:10.1016/j.lpm.2013.07.005; Ramirez 2020, DOI:10.21542/gcsp.2019.19; Dardi 2024, DOI:10.1183/13993003.01323-2024 |
| Methamphetamines | Definite | Recreational stimulant use | Endothelial injury/dysfunction; serotonin-related signaling; likely susceptibility-dependent “two-hit” biology | Usually does not remit reliably; stop exposure, start PAH therapy when indicated, and refer for substance-use treatment; associated with worse hemodynamics/outcomes (dardi2024riskstratificationand pages 22-24, iii2020drugandtoxininduced pages 5-7, chin2024treatmentalgorithmfor pages 11-12, iwata2024trendsandpatterns pages 1-2) | Ramirez 2020, DOI:10.21542/gcsp.2019.19; Dardi 2024, DOI:10.1183/13993003.01323-2024; Iwata 2024, DOI:10.3389/fcvm.2024.1445193; Chin 2024, DOI:10.1183/13993003.01325-2024 |
| Dasatinib | Definite | BCR-ABL tyrosine kinase inhibitor for CML/ALL | Endothelial dysfunction and kinase off-target vascular toxicity | Stop agent; partial/full reversal reported in some patients; observe 3–4 months if low risk, otherwise initiate PAH therapy (dardi2024riskstratificationand pages 22-24, dardi2024riskstratificationand pages 66-68, chin2024treatmentalgorithmfor pages 11-12, shah2023newdrugsand pages 11-13) | Dardi 2024, DOI:10.1183/13993003.01323-2024; Chin 2024, DOI:10.1183/13993003.01325-2024; Shah 2023, DOI:10.3390/ijms24065850 |
| Toxic rapeseed oil | Definite | Toxic oil exposure outbreak | Toxin-mediated pulmonary vascular injury; some cases may overlap with venous/capillary involvement | Exposure cessation/supportive care; historical outbreak supports causality (dardi2024riskstratificationand pages 22-24, iii2020drugandtoxininduced pages 1-3) | Ramirez 2020, DOI:10.21542/gcsp.2019.19; Dardi 2024, DOI:10.1183/13993003.01323-2024 |
| Amphetamines (non-methamphetamine) | Possible | Prescription/illicit stimulants | Mechanistic similarity to methamphetamine and anorexigens; monoamine/serotonin effects | Stop exposure; causality weaker than methamphetamine; evaluate/treat persistent PAH conventionally (dardi2024riskstratificationand pages 22-24, seferian2013drugsinducedpulmonary pages 1-2) | Dardi 2024, DOI:10.1183/13993003.01323-2024; Seferian 2013, DOI:10.1016/j.lpm.2013.07.005 |
| Interferon-α / Interferon-β | Possible | Antiviral/immunomodulatory therapy | Endothelial dysfunction and immune-mediated vascular injury | Stop agent when feasible; partial/full reversal has been reported; if no normalization after 3–4 months, initiate PAH therapy (dardi2024riskstratificationand pages 22-24, dardi2024riskstratificationand pages 66-68, chin2024treatmentalgorithmfor pages 11-12, iii2020drugandtoxininduced pages 15-17) | Dardi 2024, DOI:10.1183/13993003.01323-2024; Chin 2024, DOI:10.1183/13993003.01325-2024; Ramirez 2020, DOI:10.21542/gcsp.2019.19 |
| Bosutinib / Ponatinib | Possible | Later-generation BCR-ABL tyrosine kinase inhibitors | Endothelial/vascular toxicity analogous to dasatinib | Consider drug withdrawal and specialist reassessment; manage persistent disease as PAH (dardi2024riskstratificationand pages 22-24, hlavaty2022identifyingnewdrugs pages 1-2) | Dardi 2024, DOI:10.1183/13993003.01323-2024; Hlavaty 2022, DOI:10.1111/bcp.15436 |
| Alkylating agents (cyclophosphamide, mitomycin C) | Possible | Chemotherapy | Pulmonary veno-occlusive disease (PVOD)/capillary injury rather than classic isolated arterial disease | Stop culprit when possible; high caution because PVOD phenotype may worsen with vasodilators; specialist evaluation required (dardi2024riskstratificationand pages 22-24, iii2020drugandtoxininduced pages 15-17, dardi2024riskstratificationand pages 66-68) | Dardi 2024, DOI:10.1183/13993003.01323-2024; Ramirez 2020, DOI:10.21542/gcsp.2019.19 |
| Leflunomide | Possible | DMARD for rheumatologic disease | Unclear; pharmacovigilance signal with plausible vascular toxicity | Case-based reversibility reported after withdrawal; confirm alternative causes and monitor hemodynamics (dardi2024riskstratificationand pages 22-24, hlavaty2022identifyingnewdrugs pages 1-2, iii2020drugandtoxininduced pages 17-19) | Dardi 2024, DOI:10.1183/13993003.01323-2024; Hlavaty 2022, DOI:10.1111/bcp.15436; Ramirez 2020, DOI:10.21542/gcsp.2019.19 |
| Direct-acting antivirals for HCV (e.g., sofosbuvir) | Possible | Antiviral therapy for hepatitis C | Mechanism unclear; limited case reports, often confounded | Consider withdrawal if suspected; causality remains uncertain (dardi2024riskstratificationand pages 22-24, iii2020drugandtoxininduced pages 15-17, iii2020drugandtoxininduced pages 17-19) | Dardi 2024, DOI:10.1183/13993003.01323-2024; Ramirez 2020, DOI:10.21542/gcsp.2019.19 |
| Cocaine | Possible | Recreational stimulant; sometimes levamisole-adulterated | Vasoconstriction/endothelial injury; adulterant levamisole may be metabolized to aminorex | Stop exposure; assess for mixed stimulant/toxin exposure; evidence remains weaker than for methamphetamine (dardi2024riskstratificationand pages 22-24, iii2020drugandtoxininduced pages 17-19, mcgee2018drugassociatedpulmonaryarterial pages 7-8) | Dardi 2024, DOI:10.1183/13993003.01323-2024; Ramirez 2020, DOI:10.21542/gcsp.2019.19; McGee 2018, DOI:10.1080/15563650.2018.1447119 |
| L-tryptophan / St John’s Wort / Qing-Dai (indirubin) | Possible | Supplements/herbal exposures | Contaminant-related injury (L-tryptophan); serotonergic or other vasoactive signaling; unclear for some herbal products | Stop exposure; several reports show hemodynamic improvement after discontinuation for some agents (dardi2024riskstratificationand pages 22-24, iii2020drugandtoxininduced pages 15-17, iii2020drugandtoxininduced pages 17-19) | Dardi 2024, DOI:10.1183/13993003.01323-2024; Ramirez 2020, DOI:10.21542/gcsp.2019.19 |
Table: This table summarizes the main drugs and toxins linked to pulmonary arterial hypertension, prioritizing the current definite versus possible classifications and the most relevant mechanistic and management implications. It is useful for quickly distinguishing well-established culprits from emerging or lower-certainty signals.
The ERJ 2024 PAH treatment algorithm figure provides a practical overview of risk-stratified initial therapy and escalation strategy used in real-world PAH programs. (chin2024treatmentalgorithmfor media 169fd8c9)
References
(dardi2024riskstratificationand pages 22-24): Fabio Dardi, Athénaïs Boucly, Raymond Benza, Robert Frantz, Valentina Mercurio, Horst Olschewski, Göran Rådegran, Lewis J. Rubin, and Marius M. Hoeper. Risk stratification and treatment goals in pulmonary arterial hypertension. The European Respiratory Journal, 64:2401323, Aug 2024. URL: https://doi.org/10.1183/13993003.01323-2024, doi:10.1183/13993003.01323-2024. This article has 112 citations.
(dardi2024riskstratificationand pages 66-68): Fabio Dardi, Athénaïs Boucly, Raymond Benza, Robert Frantz, Valentina Mercurio, Horst Olschewski, Göran Rådegran, Lewis J. Rubin, and Marius M. Hoeper. Risk stratification and treatment goals in pulmonary arterial hypertension. The European Respiratory Journal, 64:2401323, Aug 2024. URL: https://doi.org/10.1183/13993003.01323-2024, doi:10.1183/13993003.01323-2024. This article has 112 citations.
(chin2024treatmentalgorithmfor pages 11-12): Kelly M. Chin, Sean P. Gaine, Christian Gerges, Zhi-Cheng Jing, Stephen C. Mathai, Yuichi Tamura, Vallerie V. McLaughlin, and Olivier Sitbon. Treatment algorithm for pulmonary arterial hypertension. The European Respiratory Journal, 64:2401325, Aug 2024. URL: https://doi.org/10.1183/13993003.01325-2024, doi:10.1183/13993003.01325-2024. This article has 228 citations.
(iwata2024trendsandpatterns pages 1-2): Hiroshi Iwata, Y. Chikata, Mohammad Alfrad, Nobel Bhuiyan, Amanda Husein, Jolie A Boullion, Md. Ismail Hossain, Diensn Xing, Md Tareq Ferdous Khan, M. Bhuiyan, Gopi K. Kolluru, Md Mosta fi zur Rahman Bhuiyan, Nicholas E. Goeders, Steven A. Conrad, J. Vanchiere, A. W. Orr, C. Kevil, and Mohammad Alfrad Nobel. Trends and patterns in pulmonary arterial hypertension-associated hospital admissions among methamphetamine users: a decade-long study. Frontiers in Cardiovascular Medicine, Oct 2024. URL: https://doi.org/10.3389/fcvm.2024.1445193, doi:10.3389/fcvm.2024.1445193. This article has 5 citations and is from a peer-reviewed journal.
(chin2024treatmentalgorithmfor pages 7-8): Kelly M. Chin, Sean P. Gaine, Christian Gerges, Zhi-Cheng Jing, Stephen C. Mathai, Yuichi Tamura, Vallerie V. McLaughlin, and Olivier Sitbon. Treatment algorithm for pulmonary arterial hypertension. The European Respiratory Journal, 64:2401325, Aug 2024. URL: https://doi.org/10.1183/13993003.01325-2024, doi:10.1183/13993003.01325-2024. This article has 228 citations.
(chin2024treatmentalgorithmfor pages 2-3): Kelly M. Chin, Sean P. Gaine, Christian Gerges, Zhi-Cheng Jing, Stephen C. Mathai, Yuichi Tamura, Vallerie V. McLaughlin, and Olivier Sitbon. Treatment algorithm for pulmonary arterial hypertension. The European Respiratory Journal, 64:2401325, Aug 2024. URL: https://doi.org/10.1183/13993003.01325-2024, doi:10.1183/13993003.01325-2024. This article has 228 citations.
(iii2020drugandtoxininduced pages 1-3): Ramon L Ramirez III, Christopher A Thomas, Ryan J Anderson, Roberto J Bernardo, Ahmed Al-Motarreb, Jassim Al-Suwaidi, Roham T Zamanian, and Vinicio A De Jesus Perez. Drug- and toxin-induced pulmonary arterial hypertension: current state of the literature. Global Cardiology Science and Practice, Feb 2020. URL: https://doi.org/10.21542/gcsp.2019.19, doi:10.21542/gcsp.2019.19. This article has 3 citations.
(shafeghat2025stateofthe pages 2-4): Melika Shafeghat, Yasmin Raza, Roberta Catania, Amir Ali Rahsepar, Blair Tilkens, Michael J. Cuttica, Benjamin H. Freed, Jingbo Dai, You-Yang Zhao, and James C. Carr. State of the art in pulmonary arterial hypertension: molecular basis, imaging modalities, and right heart failure treatment. Biomedicines, 13:1773, Jul 2025. URL: https://doi.org/10.3390/biomedicines13071773, doi:10.3390/biomedicines13071773. This article has 5 citations.
(chin2024treatmentalgorithmfor pages 5-7): Kelly M. Chin, Sean P. Gaine, Christian Gerges, Zhi-Cheng Jing, Stephen C. Mathai, Yuichi Tamura, Vallerie V. McLaughlin, and Olivier Sitbon. Treatment algorithm for pulmonary arterial hypertension. The European Respiratory Journal, 64:2401325, Aug 2024. URL: https://doi.org/10.1183/13993003.01325-2024, doi:10.1183/13993003.01325-2024. This article has 228 citations.
(dardi2024riskstratificationand pages 21-22): Fabio Dardi, Athénaïs Boucly, Raymond Benza, Robert Frantz, Valentina Mercurio, Horst Olschewski, Göran Rådegran, Lewis J. Rubin, and Marius M. Hoeper. Risk stratification and treatment goals in pulmonary arterial hypertension. The European Respiratory Journal, 64:2401323, Aug 2024. URL: https://doi.org/10.1183/13993003.01323-2024, doi:10.1183/13993003.01323-2024. This article has 112 citations.
(chin2024treatmentalgorithmfor pages 1-2): Kelly M. Chin, Sean P. Gaine, Christian Gerges, Zhi-Cheng Jing, Stephen C. Mathai, Yuichi Tamura, Vallerie V. McLaughlin, and Olivier Sitbon. Treatment algorithm for pulmonary arterial hypertension. The European Respiratory Journal, 64:2401325, Aug 2024. URL: https://doi.org/10.1183/13993003.01325-2024, doi:10.1183/13993003.01325-2024. This article has 228 citations.
(iii2020drugandtoxininduced pages 19-21): Ramon L Ramirez III, Christopher A Thomas, Ryan J Anderson, Roberto J Bernardo, Ahmed Al-Motarreb, Jassim Al-Suwaidi, Roham T Zamanian, and Vinicio A De Jesus Perez. Drug- and toxin-induced pulmonary arterial hypertension: current state of the literature. Global Cardiology Science and Practice, Feb 2020. URL: https://doi.org/10.21542/gcsp.2019.19, doi:10.21542/gcsp.2019.19. This article has 3 citations.
(seferian2013drugsinducedpulmonary pages 2-3): Andrei Seferian, Marie-Camille Chaumais, Laurent Savale, Sven Günther, Pascale Tubert-Bitter, Marc Humbert, and David Montani. Drugs induced pulmonary arterial hypertension. Presse medicale, 42 9 Pt 2:e303-10, Sep 2013. URL: https://doi.org/10.1016/j.lpm.2013.07.005, doi:10.1016/j.lpm.2013.07.005. This article has 54 citations and is from a peer-reviewed journal.
(dardi2024riskstratificationand pages 24-25): Fabio Dardi, Athénaïs Boucly, Raymond Benza, Robert Frantz, Valentina Mercurio, Horst Olschewski, Göran Rådegran, Lewis J. Rubin, and Marius M. Hoeper. Risk stratification and treatment goals in pulmonary arterial hypertension. The European Respiratory Journal, 64:2401323, Aug 2024. URL: https://doi.org/10.1183/13993003.01323-2024, doi:10.1183/13993003.01323-2024. This article has 112 citations.
(coman2025updatesonthe pages 1-2): Ioan Mircea Coman, Roxana Enache, Georgiana Olaru, Raluca Rancea, Tudor Constantinescu, Andrei Neagu, Miron Al. Bogdan, Ioan Ţilea, Andreea Varga, Nicoleta Bertici, Ovidiu Fira-Mladinescu, Anda Tesloianu, Alexandru Steriade, and Dragos Bumbacea. Updates on the therapeutic approach to pulmonary arterial hypertension. Romanian Journal of Cardiology, 35:225-230, Dec 2025. URL: https://doi.org/10.2478/rjc-2025-0035, doi:10.2478/rjc-2025-0035. This article has 0 citations.
(dardi2024riskstratificationand pages 31-32): Fabio Dardi, Athénaïs Boucly, Raymond Benza, Robert Frantz, Valentina Mercurio, Horst Olschewski, Göran Rådegran, Lewis J. Rubin, and Marius M. Hoeper. Risk stratification and treatment goals in pulmonary arterial hypertension. The European Respiratory Journal, 64:2401323, Aug 2024. URL: https://doi.org/10.1183/13993003.01323-2024, doi:10.1183/13993003.01323-2024. This article has 112 citations.
(iwata2024trendsandpatterns pages 3-4): Hiroshi Iwata, Y. Chikata, Mohammad Alfrad, Nobel Bhuiyan, Amanda Husein, Jolie A Boullion, Md. Ismail Hossain, Diensn Xing, Md Tareq Ferdous Khan, M. Bhuiyan, Gopi K. Kolluru, Md Mosta fi zur Rahman Bhuiyan, Nicholas E. Goeders, Steven A. Conrad, J. Vanchiere, A. W. Orr, C. Kevil, and Mohammad Alfrad Nobel. Trends and patterns in pulmonary arterial hypertension-associated hospital admissions among methamphetamine users: a decade-long study. Frontiers in Cardiovascular Medicine, Oct 2024. URL: https://doi.org/10.3389/fcvm.2024.1445193, doi:10.3389/fcvm.2024.1445193. This article has 5 citations and is from a peer-reviewed journal.
(correale2025pathophysiologyofpulmonary pages 2-4): Michele Correale, Valentina Mercurio, Ester Maria Lucia Bevere, Beatrice Pezzuto, Lucia Tricarico, Umberto Attanasio, Angela Raucci, Anne Lise Ferrara, Stefania Loffredo, Claudio Puteo, Massimo Iacoviello, Maurizio Margaglione, Natale Daniele Brunetti, Carlo Gabriele Tocchetti, Piergiuseppe Agostoni, Claudio Mussolino, and Maria Cristina Vinci. Pathophysiology of pulmonary arterial hypertension: focus on vascular endothelium as a potential therapeutic target. International Journal of Molecular Sciences, 26:9631, Oct 2025. URL: https://doi.org/10.3390/ijms26199631, doi:10.3390/ijms26199631. This article has 8 citations.
(iii2020drugandtoxininduced pages 7-10): Ramon L Ramirez III, Christopher A Thomas, Ryan J Anderson, Roberto J Bernardo, Ahmed Al-Motarreb, Jassim Al-Suwaidi, Roham T Zamanian, and Vinicio A De Jesus Perez. Drug- and toxin-induced pulmonary arterial hypertension: current state of the literature. Global Cardiology Science and Practice, Feb 2020. URL: https://doi.org/10.21542/gcsp.2019.19, doi:10.21542/gcsp.2019.19. This article has 3 citations.
(shah2023newdrugsand pages 11-13): Aangi J. Shah, Taylor Beckmann, Mounica Vorla, and Dinesh K. Kalra. New drugs and therapies in pulmonary arterial hypertension. International Journal of Molecular Sciences, 24:5850, Mar 2023. URL: https://doi.org/10.3390/ijms24065850, doi:10.3390/ijms24065850. This article has 71 citations.
(iwata2024trendsandpatterns pages 6-7): Hiroshi Iwata, Y. Chikata, Mohammad Alfrad, Nobel Bhuiyan, Amanda Husein, Jolie A Boullion, Md. Ismail Hossain, Diensn Xing, Md Tareq Ferdous Khan, M. Bhuiyan, Gopi K. Kolluru, Md Mosta fi zur Rahman Bhuiyan, Nicholas E. Goeders, Steven A. Conrad, J. Vanchiere, A. W. Orr, C. Kevil, and Mohammad Alfrad Nobel. Trends and patterns in pulmonary arterial hypertension-associated hospital admissions among methamphetamine users: a decade-long study. Frontiers in Cardiovascular Medicine, Oct 2024. URL: https://doi.org/10.3389/fcvm.2024.1445193, doi:10.3389/fcvm.2024.1445193. This article has 5 citations and is from a peer-reviewed journal.
(iii2020drugandtoxininduced pages 5-7): Ramon L Ramirez III, Christopher A Thomas, Ryan J Anderson, Roberto J Bernardo, Ahmed Al-Motarreb, Jassim Al-Suwaidi, Roham T Zamanian, and Vinicio A De Jesus Perez. Drug- and toxin-induced pulmonary arterial hypertension: current state of the literature. Global Cardiology Science and Practice, Feb 2020. URL: https://doi.org/10.21542/gcsp.2019.19, doi:10.21542/gcsp.2019.19. This article has 3 citations.
(dardi2024riskstratificationand pages 68-69): Fabio Dardi, Athénaïs Boucly, Raymond Benza, Robert Frantz, Valentina Mercurio, Horst Olschewski, Göran Rådegran, Lewis J. Rubin, and Marius M. Hoeper. Risk stratification and treatment goals in pulmonary arterial hypertension. The European Respiratory Journal, 64:2401323, Aug 2024. URL: https://doi.org/10.1183/13993003.01323-2024, doi:10.1183/13993003.01323-2024. This article has 112 citations.
(chin2024treatmentalgorithmfor media 169fd8c9): Kelly M. Chin, Sean P. Gaine, Christian Gerges, Zhi-Cheng Jing, Stephen C. Mathai, Yuichi Tamura, Vallerie V. McLaughlin, and Olivier Sitbon. Treatment algorithm for pulmonary arterial hypertension. The European Respiratory Journal, 64:2401325, Aug 2024. URL: https://doi.org/10.1183/13993003.01325-2024, doi:10.1183/13993003.01325-2024. This article has 228 citations.
(shah2023newdrugsand pages 16-17): Aangi J. Shah, Taylor Beckmann, Mounica Vorla, and Dinesh K. Kalra. New drugs and therapies in pulmonary arterial hypertension. International Journal of Molecular Sciences, 24:5850, Mar 2023. URL: https://doi.org/10.3390/ijms24065850, doi:10.3390/ijms24065850. This article has 71 citations.
(shah2023newdrugsand pages 18-19): Aangi J. Shah, Taylor Beckmann, Mounica Vorla, and Dinesh K. Kalra. New drugs and therapies in pulmonary arterial hypertension. International Journal of Molecular Sciences, 24:5850, Mar 2023. URL: https://doi.org/10.3390/ijms24065850, doi:10.3390/ijms24065850. This article has 71 citations.
(yeh2025molecularpathogenesisof pages 18-19): Fu-Chiang Yeh, I-Ting Tsai, and I-Tsu Chyuan. Molecular pathogenesis of connective tissue disease-associated pulmonary arterial hypertension: a narrative review. Biomolecules, 15:772, May 2025. URL: https://doi.org/10.3390/biom15060772, doi:10.3390/biom15060772. This article has 0 citations.
(hlavaty2022identifyingnewdrugs pages 7-8): Alex Hlavaty, Matthieu Roustit, David Montani, Marie‐Camille Chaumais, Christophe Guignabert, Marc Humbert, Jean‐Luc Cracowski, and Charles Khouri. Identifying new drugs associated with pulmonary arterial hypertension: a who pharmacovigilance database disproportionality analysis. British Journal of Clinical Pharmacology, 88:5227-5237, Jul 2022. URL: https://doi.org/10.1111/bcp.15436, doi:10.1111/bcp.15436. This article has 28 citations and is from a domain leading peer-reviewed journal.
(seferian2013drugsinducedpulmonary pages 1-2): Andrei Seferian, Marie-Camille Chaumais, Laurent Savale, Sven Günther, Pascale Tubert-Bitter, Marc Humbert, and David Montani. Drugs induced pulmonary arterial hypertension. Presse medicale, 42 9 Pt 2:e303-10, Sep 2013. URL: https://doi.org/10.1016/j.lpm.2013.07.005, doi:10.1016/j.lpm.2013.07.005. This article has 54 citations and is from a peer-reviewed journal.
(iii2020drugandtoxininduced pages 15-17): Ramon L Ramirez III, Christopher A Thomas, Ryan J Anderson, Roberto J Bernardo, Ahmed Al-Motarreb, Jassim Al-Suwaidi, Roham T Zamanian, and Vinicio A De Jesus Perez. Drug- and toxin-induced pulmonary arterial hypertension: current state of the literature. Global Cardiology Science and Practice, Feb 2020. URL: https://doi.org/10.21542/gcsp.2019.19, doi:10.21542/gcsp.2019.19. This article has 3 citations.
(hlavaty2022identifyingnewdrugs pages 1-2): Alex Hlavaty, Matthieu Roustit, David Montani, Marie‐Camille Chaumais, Christophe Guignabert, Marc Humbert, Jean‐Luc Cracowski, and Charles Khouri. Identifying new drugs associated with pulmonary arterial hypertension: a who pharmacovigilance database disproportionality analysis. British Journal of Clinical Pharmacology, 88:5227-5237, Jul 2022. URL: https://doi.org/10.1111/bcp.15436, doi:10.1111/bcp.15436. This article has 28 citations and is from a domain leading peer-reviewed journal.
(iii2020drugandtoxininduced pages 17-19): Ramon L Ramirez III, Christopher A Thomas, Ryan J Anderson, Roberto J Bernardo, Ahmed Al-Motarreb, Jassim Al-Suwaidi, Roham T Zamanian, and Vinicio A De Jesus Perez. Drug- and toxin-induced pulmonary arterial hypertension: current state of the literature. Global Cardiology Science and Practice, Feb 2020. URL: https://doi.org/10.21542/gcsp.2019.19, doi:10.21542/gcsp.2019.19. This article has 3 citations.
(mcgee2018drugassociatedpulmonaryarterial pages 7-8): Michael McGee, Nicholas Whitehead, Jennifer Martin, and Nicholas Collins. Drug-associated pulmonary arterial hypertension. Clinical Toxicology, 56:801-809, Mar 2018. URL: https://doi.org/10.1080/15563650.2018.1447119, doi:10.1080/15563650.2018.1447119. This article has 98 citations and is from a peer-reviewed journal.